vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and NETSTREIT Corp. (NTST). Click either name above to swap in a different company.

NETSTREIT Corp. is the larger business by last-quarter revenue ($57.1M vs $38.3M, roughly 1.5× ImmunityBio, Inc.). NETSTREIT Corp. runs the higher net margin — 10.0% vs -161.8%, a 171.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 24.3%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

NETSTREIT Corp. is a US-headquartered real estate investment trust (REIT) that specializes in acquiring and operating a diversified portfolio of single-tenant net lease commercial properties. Its asset portfolio covers retail, industrial and office categories, primarily catering to investment-grade corporate tenants across the United States market.

IBRX vs NTST — Head-to-Head

Bigger by revenue
NTST
NTST
1.5× larger
NTST
$57.1M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+382.7% gap
IBRX
407.0%
24.3%
NTST
Higher net margin
NTST
NTST
171.8% more per $
NTST
10.0%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
NTST
NTST
Revenue
$38.3M
$57.1M
Net Profit
$-61.9M
$5.7M
Gross Margin
99.0%
Operating Margin
-169.0%
34.1%
Net Margin
-161.8%
10.0%
Revenue YoY
407.0%
24.3%
Net Profit YoY
-4.7%
235.9%
EPS (diluted)
$-0.06
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
NTST
NTST
Q1 26
$57.1M
Q4 25
$38.3M
$52.5M
Q3 25
$32.1M
$48.3M
Q2 25
$26.4M
$48.3M
Q1 25
$16.5M
$45.9M
Q4 24
$7.6M
$44.1M
Q3 24
$6.1M
$41.4M
Q2 24
$39.6M
Net Profit
IBRX
IBRX
NTST
NTST
Q1 26
$5.7M
Q4 25
$-61.9M
$1.3M
Q3 25
$-67.3M
$618.0K
Q2 25
$-92.6M
$3.3M
Q1 25
$-129.6M
$1.7M
Q4 24
$-59.2M
$-5.4M
Q3 24
$-85.7M
$-5.3M
Q2 24
$-2.3M
Gross Margin
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Operating Margin
IBRX
IBRX
NTST
NTST
Q1 26
34.1%
Q4 25
-169.0%
2.6%
Q3 25
-173.5%
1.3%
Q2 25
-269.8%
6.8%
Q1 25
-390.1%
3.7%
Q4 24
-919.0%
-12.3%
Q3 24
-1314.3%
-12.8%
Q2 24
-5.8%
Net Margin
IBRX
IBRX
NTST
NTST
Q1 26
10.0%
Q4 25
-161.8%
2.5%
Q3 25
-209.8%
1.3%
Q2 25
-350.3%
6.8%
Q1 25
-784.9%
3.7%
Q4 24
-783.4%
-12.3%
Q3 24
-1404.0%
-12.8%
Q2 24
-5.8%
EPS (diluted)
IBRX
IBRX
NTST
NTST
Q1 26
$0.32
Q4 25
$-0.06
$0.01
Q3 25
$-0.07
$0.01
Q2 25
$-0.10
$0.04
Q1 25
$-0.15
$0.02
Q4 24
$-0.08
$-0.07
Q3 24
$-0.14
$-0.07
Q2 24
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
NTST
NTST
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$1.5B
Total Assets
$501.9M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Total Debt
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$926.6M
Q1 25
$913.3M
Q4 24
$868.3M
Q3 24
$778.7M
Q2 24
$726.2M
Stockholders' Equity
IBRX
IBRX
NTST
NTST
Q1 26
$1.5B
Q4 25
$-500.5M
$1.4B
Q3 25
$-524.3M
$1.3B
Q2 25
$-570.7M
$1.3B
Q1 25
$-591.4M
$1.3B
Q4 24
$-489.1M
$1.3B
Q3 24
$-745.1M
$1.3B
Q2 24
$1.3B
Total Assets
IBRX
IBRX
NTST
NTST
Q1 26
$2.8B
Q4 25
$501.9M
$2.6B
Q3 25
$519.0M
$2.5B
Q2 25
$402.1M
$2.3B
Q1 25
$303.8M
$2.3B
Q4 24
$382.9M
$2.3B
Q3 24
$364.6M
$2.2B
Q2 24
$2.1B
Debt / Equity
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
0.76×
Q3 25
0.84×
Q2 25
0.70×
Q1 25
0.70×
Q4 24
0.65×
Q3 24
0.58×
Q2 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
NTST
NTST
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
$-70.4M
$109.5M
Q3 25
$-68.9M
$28.0M
Q2 25
$-79.7M
$30.6M
Q1 25
$-85.9M
$22.1M
Q4 24
$-85.1M
$90.2M
Q3 24
$-98.8M
$25.1M
Q2 24
$25.4M
Free Cash Flow
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
FCF Margin
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Capex Intensity
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Cash Conversion
IBRX
IBRX
NTST
NTST
Q1 26
Q4 25
82.46×
Q3 25
45.27×
Q2 25
9.36×
Q1 25
13.06×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

NTST
NTST

Rental revenue (including reimbursable)$54.0M95%
Other$3.0M5%

Related Comparisons